Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9009229 | 0.96 | LMNA (0.51) | LMNACYP2C19HIF1AABCB1HPGD | |
| Hydrochloric Acid SCHEMBL8857417 | 0.95 | LMNA (0.50) | LMNACYP2C19HIF1AABCB1HPGD | |
| SCHEMBL9009212 | 0.95 | LMNA (0.50) | LMNACYP2C19HIF1AABCB1HPGD | |
| SCHEMBL13336860 | 0.94 | LMNA (0.49) | LMNACYP2C19HIF1AABCB1 | |
| SCHEMBL7056140 | 0.93 | LMNA (0.46) | LMNACYP2C19HIF1AABCB1HPGD | |
| SCHEMBL12871741 | 0.91 | LMNA (0.65) | LMNACYP2C19HIF1A | |
| SCHEMBL1019287 | 0.90 | LMNA (0.54) | LMNACYP2C19HIF1A | |
| SCHEMBL9317092 | 0.89 | LMNA (0.43) | LMNACYP2C19HIF1AABCB1ALDH1A1 | |
| SCHEMBL28880451 | 0.89 | LMNA (0.43) | LMNACYP2C19HIF1AABCB1ALDH1A1 | |
| SCHEMBL12871782 | 0.89 | LMNA (0.41) | LMNACYP2C19HIF1AABCB1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420858-B2 | Process for preparation of iopromide | LG LIFE SCIENCES LTD. (KR) | 2013-04-16 | — | — | US | disclosed |
| US-20110034730-A1 | NOVEL PROCESS FOR PREPARATION OF IOPROMIDE | LG LIFE SCIENCES LTD. (KR) | 2011-02-10 | — | — | US | disclosed |
| WO-2010060941-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010060941-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-06-03 | — | — | WO | disclosed |
| EP-0410974-A4 | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | — | 1991-09-11 | — | — | EP | disclosed |
| EP-0410974-A1 | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | MALLINCKRODT, INC. (US) | 1991-02-06 | — | — | EP | disclosed |
| WO-1989008101-A1 | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | MALLINCKRODT, INC. (US) | 1989-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034730-A1 | NOVEL PROCESS FOR PREPARATION OF IOPROMIDE | PPIP5K2, SLC5A11, SLC10A2 | LMNA 1996/4885CYP2C19 286/4885HIF1A 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.